RET rs121913638: Understanding the p.Cys634Arg Variant
The genetic variant rs121913638, also known as p.Cys634Arg, is a specific change in the RET proto-oncogene. It is recognized as a pathogenic variant associated with the development of Multiple Endocrine Neoplasia type 2A (MEN2A), an inherited condition that increases the risk of certain endocrine tumors.
What each genotype means
Typical risk profile
You carry two copies of the standard reference allele at this position in the RET gene. This genotype is not associated with the hereditary endocrine cancer predisposition linked to multiple endocrine neoplasia type 2A (MEN2A) or familial medullary thyroid carcinoma. Your baseline risk for these specific inherited conditions remains consistent with the general population.
Carried by more than 99.9% of individuals across all major global populations.
MEN2A predisposition carrier
You carry one copy of the pathogenic missense variant (p.Cys634Arg) in the RET gene. Research links this heterozygous genotype to multiple endocrine neoplasia type 2A (MEN2A), conferring a very high lifetime predisposition to medullary thyroid carcinoma and increased risk for pheochromocytoma and hyperparathyroidism. Because this variant carries significant clinical implications, individuals with this genotype are advised to consult a clinical geneticist or endocrine oncology specialist.
Extremely rare worldwide, identified in far fewer than 1 in 10,000 individuals in general population databases.
What is the rs121913638 Variant?
The variant rs121913638 represents a specific alteration in the DNA sequence of the RET gene, where a thymine is replaced by a cytosine. This change results in an amino acid substitution at position 634 of the RET protein, where cysteine is replaced by arginine (p.Cys634Arg). This variant is located in exon 11 of the RET gene. In the context of clinical genetics, this specific change is classified as pathogenic, meaning it is known to disrupt the normal function of the protein in a way that contributes to disease. Because it is a germline variant, it can be inherited from a parent or occur as a new mutation in an individual. It is primarily studied in the context of hereditary cancer syndromes, where it serves as a critical marker for clinical risk assessment.
The Role of the RET Gene
The RET gene provides instructions for producing a protein called the receptor tyrosine kinase. This protein acts as a cell-surface receptor, playing a vital role in the signaling pathways that control cell growth, differentiation, and survival. Under normal conditions, the RET protein is activated only when specific signaling molecules bind to it. However, certain mutations, such as p.Cys634Arg, can cause the RET protein to become constitutively active, meaning it remains 'turned on' even in the absence of external signals. This constant activation can lead to the uncontrolled growth and division of cells, which is a hallmark of oncogenic processes. In the thyroid and other endocrine glands, this dysregulated signaling is a primary driver for the development of tumors associated with Multiple Endocrine Neoplasia syndromes.
Clinical Associations and Evidence
Research consistently associates the rs121913638 variant with Multiple Endocrine Neoplasia type 2A (MEN2A). MEN2A is an autosomal dominant syndrome characterized by a high risk of developing medullary thyroid carcinoma (MTC), pheochromocytoma, and hyperparathyroidism. Clinical studies have indicated that the p.Cys634Arg mutation often correlates with a more aggressive clinical phenotype compared to other variants in the same region. The evidence for its pathogenicity is well-established in medical literature and clinical databases, leading to its inclusion in diagnostic testing panels for hereditary cancer predisposition. While the association with MEN2A is strong, the penetrance—the likelihood that an individual with the variant will develop clinical symptoms—can vary. Clinicians use this information to guide surveillance and management strategies for individuals and families identified as carriers of this variant.
Population Frequency
The rs121913638 variant is considered rare in the general population. It is not a common polymorphism found in the healthy public but is instead identified primarily in clinical settings among individuals or families presenting with symptoms of hereditary endocrine tumors. Because it is a pathogenic mutation associated with a specific disease syndrome, its frequency is extremely low in large-scale population databases like gnomAD. The presence of this variant is typically investigated through targeted genetic testing when there is a clinical suspicion of MEN2A, rather than through general population screening. Its rarity underscores that it is not a typical variation found in the human gene pool, but rather a specific genetic event with significant clinical implications for those who carry it.
Managing Genetic Information
If you or a family member have been identified as a carrier of the rs121913638 variant, it is essential to consult with a qualified healthcare provider, such as a genetic counselor or an endocrinologist. This information is highly specialized and carries significant implications for long-term health monitoring and potential preventative care. You cannot use this information to self-diagnose or determine personal health outcomes without professional medical guidance. Genetic testing results should always be interpreted within the context of your personal and family medical history. A clinician can help explain the risks associated with this variant, discuss appropriate screening protocols for early detection of endocrine tumors, and provide support for family members who may also be at risk. Always rely on clinical experts to translate genetic findings into actionable health plans.
How common is this variant?
The rs121913638 variant is rare in the general population, as it is a pathogenic mutation associated with hereditary cancer syndromes rather than a common genetic polymorphism.
Frequently asked questions
What is the clinical significance of the RET p.Cys634Arg variant?
The p.Cys634Arg variant is a known pathogenic mutation in the RET gene. It is strongly associated with Multiple Endocrine Neoplasia type 2A (MEN2A), a condition that increases the risk of developing specific endocrine tumors.
Is the rs121913638 variant inherited?
Yes, this variant is a germline mutation, meaning it can be passed from parents to their children. It follows an autosomal dominant inheritance pattern, meaning an individual only needs to inherit one copy of the variant to be at risk.
What should I do if I test positive for this variant?
If you test positive for this variant, you should schedule an appointment with a genetic counselor or an endocrinologist. They will provide guidance on appropriate medical surveillance and discuss the implications for your health and your family members.
Does having this variant mean I will definitely develop cancer?
While this variant is associated with a significantly increased risk of developing certain endocrine tumors, it does not guarantee that an individual will develop cancer. Clinical management focuses on early detection and proactive monitoring.
Sources & further reading
Educational information only, last refreshed 10/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121913638?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in RET
Synonymous polymorphism in the RET proto-oncogene exon 11 analyzed in medullary thyroid carcinoma and Hirschsprung disease risk models.
Associated with inherited susceptibility to multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma.
Pathogenic missense variant (p.Cys634Arg) causing Multiple Endocrine Neoplasia Type 2A (MEN2A) and familial medullary thyroid carcinoma.
Missense mutation p.Cys634Arg in RET associated with Multiple Endocrine Neoplasia Type 2A (MEN2A).
A variant located in the RET gene, which is involved in various developmental processes including those relevant to ocular health.